ATE231728T1 - Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren - Google Patents

Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren

Info

Publication number
ATE231728T1
ATE231728T1 AT99202497T AT99202497T ATE231728T1 AT E231728 T1 ATE231728 T1 AT E231728T1 AT 99202497 T AT99202497 T AT 99202497T AT 99202497 T AT99202497 T AT 99202497T AT E231728 T1 ATE231728 T1 AT E231728T1
Authority
AT
Austria
Prior art keywords
stimulators
gamma
pharmaceutical composition
composition containing
containing interferon
Prior art date
Application number
AT99202497T
Other languages
German (de)
English (en)
Inventor
Mark William James Ferguson
Vale Furness
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of ATE231728T1 publication Critical patent/ATE231728T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
AT99202497T 1995-08-18 1996-08-09 Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren ATE231728T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma

Publications (1)

Publication Number Publication Date
ATE231728T1 true ATE231728T1 (de) 2003-02-15

Family

ID=10779448

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99202497T ATE231728T1 (de) 1995-08-18 1996-08-09 Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
AT96927141T ATE208402T1 (de) 1995-08-18 1996-08-09 Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96927141T ATE208402T1 (de) 1995-08-18 1996-08-09 Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren

Country Status (12)

Country Link
EP (2) EP0845007B1 (enExample)
JP (2) JP4070809B2 (enExample)
AT (2) ATE231728T1 (enExample)
AU (1) AU713809B2 (enExample)
CA (1) CA2229590C (enExample)
DE (2) DE69616803T2 (enExample)
DK (2) DK0845007T3 (enExample)
ES (2) ES2164911T3 (enExample)
GB (1) GB2304342A (enExample)
PT (2) PT972521E (enExample)
WO (1) WO1997007136A2 (enExample)
ZA (1) ZA966953B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69927520T2 (de) 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
JP5530635B2 (ja) * 2007-02-14 2014-06-25 独立行政法人科学技術振興機構 腸管癒着抑制剤
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
JPH01502980A (ja) * 1986-06-17 1989-10-12 レイチ，スティーブン　デー ガンマインターフェロンと抗炎症剤または抗発熱剤との組合せ並びに疾患処置方法
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
SG43205A1 (en) * 1988-12-19 1997-10-17 American Cyanamid Co A method for the treatment of endotoxic shock in a mammal
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
ATE132191T1 (de) * 1989-04-19 1996-01-15 Hoffmann La Roche Auflösbare interferon-gamma-rezeptoren sowie verfahren zu deren herstellung
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
JPH05506247A (ja) * 1990-09-27 1993-09-16 シェリング・コーポレーション ヒトγインターフェロンのアンタゴニスト
WO1992014480A1 (en) * 1991-02-22 1992-09-03 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
AU5669694A (en) * 1992-11-20 1994-06-22 Schering Corporation Antagonists of human gamma interferon
EP0695189B1 (en) * 1992-12-29 1998-11-25 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
JPH09506263A (ja) * 1993-12-09 1997-06-24 アゲット，ミヒェル ＩＦＮ−γレセプターβ−鎖およびその誘導体

Also Published As

Publication number Publication date
ATE208402T1 (de) 2001-11-15
WO1997007136A2 (en) 1997-02-27
DK0972521T3 (da) 2003-05-05
HK1023516A1 (en) 2000-09-15
GB2304342A (en) 1997-03-19
ES2164911T3 (es) 2002-03-01
EP0972521B1 (en) 2003-01-29
EP0845007B1 (en) 2001-11-07
DE69626050D1 (de) 2003-03-06
JP2007119497A (ja) 2007-05-17
JP4070809B2 (ja) 2008-04-02
PT845007E (pt) 2002-03-28
DK0845007T3 (da) 2001-12-17
AU713809B2 (en) 1999-12-09
ZA966953B (en) 1998-02-16
AU6707196A (en) 1997-03-12
EP0845007A2 (en) 1998-06-03
GB9516967D0 (en) 1995-10-18
DE69626050T2 (de) 2004-01-22
EP0972521A1 (en) 2000-01-19
CA2229590A1 (en) 1997-02-27
JPH11511160A (ja) 1999-09-28
DE69616803D1 (de) 2001-12-13
DE69616803T2 (de) 2002-06-20
JP4616291B2 (ja) 2011-01-19
PT972521E (pt) 2003-06-30
WO1997007136A3 (en) 1997-08-21
CA2229590C (en) 2010-10-12
ES2192018T3 (es) 2003-09-16

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
FI973039A7 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI973279A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
IT1242170B (it) Composizione adesiva stabilizzante per protesi dentarie.
IT9048524A0 (it) Composizione adesiva stabilizzante per protesi dentarie.
ATE231728T1 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
ATE235245T1 (de) Pharmaceutische komposition
UA48958C2 (uk) 9-o-оксимові похідні еритроміцину а та фармацевтична композиція на їх основі
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
ITMI932189A0 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
ATE159171T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
DE69231263D1 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
IT9048526A0 (it) Composizione adesiva stabilizzante anidra per protesi dentarie.
ITMI931174A0 (it) Composizioni farmaceutiche per la cura della talassemia
DE59405654D1 (de) T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0972521

Country of ref document: EP

REN Ceased due to non-payment of the annual fee